Skip to Content
BioTechX-2880-x1880-dotcom-Banner_Ver-1
Event

Capgemini at BioTechX 2024

Date: 9th – 10th OCT
Location: Hall 1, Messe Basel, Switzerland
Booth: #1132

Data, meet care.

At Capgemini, we’re all about transforming data and research into real results, pushing pharma into the future while caring for humanity. That’s why we’re thrilled to be part of BioTechX Europe 2024, showcasing our R&D, Clinical Development, GenAI, and pharma innovation capabilities and expertise.

What’s BioTechX Europe?

BioTechX Europe is the go-to event for diagnostics, precision medicine, and digital transformation in pharma and healthcare. This year, it’s back in Basel, Europe’s pharma hub, with 3500 global execs, 400 speakers, and 50 start-ups all under one roof.

The event is packed with networking opportunities and insights from top pharmaceutical and biotech companies, healthcare systems providers, and academic groups.

Event highlights

  •  16 tracks of high-level content on multiomic data, personalized therapies, and data generation.
  •  Keynotes that merge diverse topics, highlighting the need for interdisciplinary collaboration in healthcare.
The full agenda can be found here

Join Our expert-led panel discussions at BioTechX

At BioTechX, we will be moderating a series of panel discussions on critical topics such as data integration, FAIR (Findable, Accessible, Interoperable, and Reusable) data principles, and digital transformation. These discussions will feature industry leaders and experts, providing valuable insights and fostering collaboration in the biotech community. Join us as we explore these pivotal areas and contribute to the advancement of biotechnology.

Making a splash

Long story short, we’re not just attending—we’re making a splash. Capgemini will have a booth and we will be on stage, showing we mean business. We’re excited to share our deep industry knowledge and innovative solutions in pharma. Plus, we’ve got some exciting content for you to download before the event—a little pre-event joy to get you pumped!

Join us at BioTechX Europe 2024 in Basel and be part of the future of biotech and pharma.

Speaking session

Dive into BioTechX themes

Innovation – what’s next, and why it matters

Innovation isn’t just a buzzword—it’s changing the game for businesses and the world around us. We’re diving into what innovation really means for businesses today, especially when it comes to building a creative culture, tackling sustainability, and exploring cutting-edge tech like synthetic biology, the metaverse, quantum tech, and blockchain. Whether you’re looking to stay ahead of the curve in business or just curious about what the future holds, we’ve got interesting content for you.

CRISPR for a better world

The Capgemini Research Institute spoke with Dr. Jennifer Doudna, Nobel Prize laureate and Professor of Biomedical Science, University of California, Berkeley.

In this interview, Dr. Doudna offers a clear understanding of CRISPR and its applications, and talks about how CRISPR can be used for a better world.

Read the interview
Accelerating Medicine R&D Cycles

Accelerating Medicine R&D Cycles

Capgemini and Sanofi set a new industry standard by accelerating clinical trials with the Act4Patients program.

Read the full story here

Clinical development

The clinical drug development market is rich with innovations such as cell and gene therapies, digital therapeutics, personalized medicine, biomarkers, and the integration of drugs and medical devices. Despite these advancements, many life sciences organizations struggle to fully benefit from them. This new era of opportunity also brings increased complexity, emphasizing the need to address core challenges related to access, speed, and effectiveness. As the clinical landscape grows more complex and competitive, it is crucial to adopt transformative strategies, advanced digital and data capabilities, and innovative trial designs to achieve next-gen clinical trials and expedite drug development success.

In this point of view we explore one key element of the development cycle – the clinical trial – and how the emergence of powerful new digital and data capabilities, as well as new trial designs, can help companies increase program efficiency, speed, and access, driving outcomes for both the business and patients.

Download here

Gen AI

Generative AI (GenAI) and other forms of Artificial intelligence (AI) are creating new opportunities to reshape the future. In the world of the data economy, organizations are embracing new landscapes of connectivity, interactions, and creations. To stay ahead they are combining data with artificial intelligence, to explore new ways of working, producing, consuming and communicating – our future. Generative AI, with its extraordinary potential, is the new contributor to this shake-up.

But how can we experience the full transformational benefits of AI while remaining ethical, protecting society and the planet, and creating a more sustainable, trustworthy, and better future for everyone? 

Generative AI for life sciences

Generative AI for life sciences

Now is the time for life sciences organizations to plan their GenAI strategy and explore carefully selected use cases in a controlled environment, so they’re ready to reap this technology’s significant benefits while not exposing themselves to unnecessary risk.

Read our report
Leading trustworthy AI in Life Sciences

Leading trustworthy AI in Life Sciences

Capgemini is proactively anticipating regulatory aspects and collaborating with clients to develop a platform compliant with future European AI legislation. By tailoring its approach to the regulated life sciences sector, Capgemini ensures its solutions meet both general AI requirements and the industry’s rigorous standards. Part 1 of this series explores the leadership needed to integrate and comply with trusted AI in life sciences, while Part 2 will offer recommendations and best practices for deploying trusted AI in this field.

Download point of view

Research and insights

Capgemini Research Institute

Engineering biology

Meet our experts

Thorsten Rall

Global Industry Lead Life Sciences, EVP
Thorsten is a global Life Science Industry Leader who oversees strategy, offers, market positioning, strategic partnerships and G2M for Capgemini in Life Sciences.

Barnabé Lecouteux

Senior Director, Data & Analytics for Intelligent Industry, Capgemini Invent
Barnabé Lecouteux has 14 years of experience leading strategic and operational projects, with a focus on Data and Artificial Intelligence (AI) topics in the life sciences. He started his career as a consultant for Capgemini on operations transformation in the services, industry and life sciences sectors. Barnabé has a total of 8 years of experience in life sciences, first at Ipsen Pharma as Director of Strategic Planning and then at Air Liquide Healthcare, where he held the positions of Head of Chronic Renal Disease BU and Director of Digital Strategy for chronic diseases.

Ivana Knyght

Director, Global Life Sciences Incubator Lead, Capgemini Invent
Ivana is an established Life Sciences leader bringing a wealth of scientific, research, clinical and data expertise gained over the past 15+ years. At Capgemini, Ivana is at the forefront of driving digital innovation, business transformation and R&D acceleration for her clients. She provides strategic and scientific expertise to develop innovative solutions by employing emerging technologies, assets and platforms. She leads CxO-level business development, strategic deal shaping, and partnership building.